Pharmaceutical and Medical Device Policy

The Medicare drug negotiation framework established under the Inflation Reduction Act is far more limited than other frameworks in seven health systems explored in this study. More

The dangers of faulty laboratory tests have been highlighted recently because of reporting on the collapse of Theranos owing to fraudulent claims… More

Six decades after its creation, the Advisory Committee on Immunization Practices carries vastly expanded responsibilities, and its recommendations carry substantially greater impact. More

Health policymakers have insufficiently addressed care for people with obesity (body mass index [BMI] ≥ 30 kg/m2) in the United States.… More

Virtually all modern medical devices now include embedded software, ranging from basic user interfaces and network connectivity to sophisticated… More

Our scoping review provides a roadmap of the questions being asked about the 340B program and an initial synthesis of the answers. More

Forty years ago, Congress enacted the Orphan Drug Act of 1983 (ODA), one of the most important and successful US laws to stimulate global life… More

Although it will not fully solve patent barriers to the access of medicines, implementation of compulsory licensing (and specifically those for the import and export of pharmaceutical products) will provide governments with another tool to safeguard their population’s public health. More

Context: The Food and Drug Administration (FDA)’s accelerated-approval pathway expedites patient access to promising treatments. However,… More

Since before Ponce de Leon’s quest for the fountain of youth that led him to discover what is now Florida and Cervantes’ Don Quixote’s likeminded search, humans have sought a way to slow or even reverse the aging process. Now, however, we have preliminary evidence that there are indeed methods of slowing down senescence. More